2023
Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchMeSH KeywordsAdultBabesia microtiBabesiosisConnecticutHumansNervous System DiseasesParasitemiaUnited StatesConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitus
2020
Parasite burden and red blood cell exchange transfusion for babesiosis
O'Bryan J, Gokhale A, Hendrickson JE, Krause PJ. Parasite burden and red blood cell exchange transfusion for babesiosis. Journal Of Clinical Apheresis 2020, 36: 127-134. PMID: 33179803, PMCID: PMC9517950, DOI: 10.1002/jca.21853.Peer-Reviewed Original ResearchConceptsEnd-organ dysfunctionPeak parasitemia levelsRed blood cell exchange transfusionParasitemia levelsExchange transfusionPeak parasitemiaDisease severityParasite burdenYale-New Haven HospitalBabesia microti parasitemiaHigh-grade parasitemiaRetrospective chart reviewBabesia microti infectionNew Haven HospitalAntimicrobial agentsChart reviewHepatic dysfunctionPatient demographicsClinical statusMedian lengthLaboratory indicatorsMicroti infectionDegree of hemolysisNineteen subjectsDysfunctionClofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts
Tuvshintulga B, Vannier E, Tayebwa DS, Gantuya S, Sivakumar T, Guswanto A, Krause PJ, Yokoyama N, Igarashi I. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. The Journal Of Infectious Diseases 2020, 222: 1027-1036. PMID: 32310272, DOI: 10.1093/infdis/jiaa195.Peer-Reviewed Original ResearchConceptsB. microti parasitesMicroti infectionHigh-grade parasitemiaDrug-resistant tuberculosisB. microtiBabesia microti infectionAdditional preclinical studiesB. microti infectionImmunocompromised hostB. microti DNAPolymerase chain reactionPreclinical studiesIncidence of babesiosisPromising drugRadical cureMinimal doseClofazimineDay 10Blood smearsBabesia microtiNovel drugsParasitemiaChain reactionMicroscopic examinationAntimicrobial agents
2019
Repeat exchange transfusion for treatment of severe babesiosis
Radcliffe C, Krause PJ, Grant M. Repeat exchange transfusion for treatment of severe babesiosis. Transfusion And Apheresis Science 2019, 58: 638-640. PMID: 31526674, DOI: 10.1016/j.transci.2019.07.010.Peer-Reviewed Case Reports and Technical NotesConceptsRepeat exchange transfusionExchange transfusionSevere babesiosisHospital day 5Second exchange transfusionBabesia microti infectionHigh feverRheumatoid arthritisMicroti infectionTransfusionDay 5Literature searchDearth of informationParasitemiaInfectionBabesiosisEtanerceptArthritisFeverClindamycinHypoxiaCasesWeeksWomen
2010
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis
1998
Persistent Parasitemia after Acute Babesiosis
Krause P, Spielman A, Telford S, Sikand V, McKay K, Christianson D, Pollack R, Brassard P, Magera J, Ryan R, Persing D. Persistent Parasitemia after Acute Babesiosis. New England Journal Of Medicine 1998, 339: 160-165. PMID: 9664092, DOI: 10.1056/nejm199807163390304.Peer-Reviewed Original ResearchConceptsDuration of parasitemiaSpecific therapySide effectsInfected peopleCommunity-based studyEpisodes of illnessProtozoan Babesia microtiBabesial DNASymptoms of babesiosisRecrudescent diseaseQuinine therapyThin blood smearsPersistent parasitemiaInfected subjectsSerologic testsIll subjectsSpecific symptomsAcute babesiosisMore monthsParasitemiaBlood smearsBabesial infectionTherapyBabesia microtiSymptoms